Press Releases

Analysis of results from EMERGE™ Phase 3 efficacy trial of STS101 ongoing; expect to communicate next steps by early 2021

- Credit Suisse - 29th Annual Healthcare Conference - November 9th -12th

- Topline data did not show statistically significant differences between either dosage strength of STS101 and placebo on co-primary endpoints of freedom from pain and most bothersome symptom at two hours post-administration

Completed treatment phase of pivotal EMERGE™ Phase 3 efficacy trial of STS101 as planned and remain on track to report top-line results in late September or early October 2020

ASCEND results expected to support STS101 NDA filing in Q4 2021

Meeting Launch date is Saturday, June 13th 2020 at 9:00am (PT)

More than 1,140 patients randomized and topline results expected in second half 2020